Tootfinder

Designing single-layer PDMS devices for micron to millimeter-scale deformations
Leon Valentin Gebhard, Alexandre S. Avaro, Gabriel Amselem, Charles N. Baroud
https://arxiv.org/abs/2605.17402 https://arxiv.org/pdf/2605.17402 https://arxiv.org/html/2605.17402
arXiv:2605.17402v1 Announce Type: new
Abstract: The elasticity of PDMS has played a central role in advancing important microfluidic technologies, ranging from early valves to sophisticated organ-on-a-chip systems. However, most deformable microfluidic devices are based on geometries that require complex multi-layer PDMS architectures and include thin membranes, leading to difficult microfabrication and poor stability. Recently, Jain, Belkadi et al. (Biofabrication 16.3 (2024): 035010) introduced a single-layer device in which a wide and long microfluidic channel was deformed by controlling the pressure in two independent and adjacent air chambers. While they demonstrated the ability to deform the channel ceiling to compress biological materials, the design parameters remain unexplored. Here, we perform a numerical study on 14,336 variants of this device and identify the height of the PDMS layer, the width of the microchannel and the width of the air chamber as the main features that determine the ceiling deformation. Three deformation modes are observed as the geometrical parameters are varied: A U shape with a central minimum, a W shape with two minima and a central maximum, or an inverse U shape with an upward-bulging single maximum. The numerical results are validated in experiments that reproduce the three shapes for the predicted geometries and demonstrate vertical ceiling deformations ranging from a few microns to the millimeter scale. The generality of this approach is demonstrated for two example applications: A fully closing single-layer microfluidic valve and an optical lens of controllable anisotropy. This work leverages the rapid prototyping enabled by 3D printing or micro-milling to open new perspectives in microfluidic actuation.
toXiv_bot_toot

Across the neuromuscular disease community, patients repeatedly tell the same story.
Therapies become available in other countries while Canadians face years of uncertainty navigating regulatory reviews, health technology assessments, negotiations, and reimbursement decisions.
Even after a therapy receives regulatory approval, access remains unpredictable, prolonged, and often dependent on where a person lives.  
The experience of the Friedreich ataxia community has become…

Is Canada's Rare Disease Promise Collapsing?   - Muscular Dystrophy Canada
Last year, in Healthy Debate, we warned that Canadians were increasingly finding themselves in an impossible position: treatments could be approved, yet remain inaccessible. One year later, the experience of Canadians living with Friedreich ataxia has become a powerful example of exactly that reality.   Health Canada approved SKYCLARYS (omaveloxolone) in March 2025 through a Priority Review. Canada’s […]

Nithya Raman has "a master’s degree in urban planning from the Massachusetts Institute of Technology" - I'd vote for her
Incumbent LA Mayor Karen Bass will face a challenge from the left in November | Courthouse News Service
https://www.courthousenews.com/incumbent-la-mayor-karen-bass-will-face-a-challenge-from-the-left-in-november/

Watching this old (1974) video about futuristic technology in Romania, I spot the pride of Skokie at 18:33 https://youtu.be/BmVN5NRx3wg?t=1112